Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Study reveals several compounds that block cancer cell invasion

Metastasis-the spread of cancer from the place where it first started to another place in the body-is the most common reason that cancer treatments fail. To metastasize, some types of cancer cells rely on invadopodia, cellular membrane projections that act like feet, helping them "walk" away from the primary tumor and invade surrounding tissues.

27 Jul 2011

Natural formula can fight against highly invasive breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.

19 Jul 2011

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.

15 Jul 2011

New method for determining breast cancer metastasis

Researchers from the MIRA research institute at the University of Twente, together with their research partners, have been awarded a €1.4 million grant to develop a new method of determining whether patients with breast cancer have developed secondary tumours.

15 Jul 2011

Study: Early-stage melanomas can help predict tumor metastasis

Wanderlust in a person can be admirable or romantic. In a cancerous tumor, it may be lethal. Most deaths from cancer result from tumor cells that have strayed from their original location to insinuate their way into distant tissues. With few exceptions, however, doctors have little way of determining whether a newly formed tumor is more likely to remain idle or send invader cells to other parts of the body.

15 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

New animal model for studying development of testicular germ cell tumors

A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.

12 Jul 2011

AACR Conference on Frontiers in Basic Cancer Research to be held in San Francisco

For more than 100 years, the American Association for Cancer Research has been the premier leader in the basic science of cancer research.

12 Jul 2011

Specific miRNAs play a key role in melanoma metastasis

Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs play in melanoma metastasis to simultaneously cause cancer cells to invade and immunosuppress the human body's ability to fight abnormal cells.

12 Jul 2011

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

7 Jul 2011

Understanding glioblastoma at the genetic, molecular level

Glioblastoma is the most common and most lethal form of brain tumor in people. Research published in the International Journal of Computational Biology and Drug Design offers a novel way to determine what biological functions go awry when the tumor first begins to form.

7 Jul 2011

LCMC finds 9.6% of lung cancer patients with ALK rearrangement

ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Scientists to test whether fish oil can prevent metastatic bowel cancer

Researchers from the University of Leeds will carry out a series of experiments to see whether fish oil can prevent or treat the spread of bowel cancer to the liver.

2 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Scientists discover enzyme that can regulate breast cancer development

Researchers at Cold Spring Harbor Laboratory (CSHL) have identified an enzyme that appears to be a significant regulator of breast cancer development. Called PTPN23, the enzyme is a member of a family called protein tyrosine phosphatases, or PTPs, that plays a fundamental role in switching cell signaling on and off.

1 Jul 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011